Tag: biotech
-
Canntab (PILL.C) yeets another patent for hard-pressed, long release cannabis pills
I’ve made no secret of the fact that the Canadian cannabis market frequently annoys the hell out of me. What I want is for it to be a mature space that more and more adults are making use of, and that is free to innovate, free to be excellent, free to market itself properly, and…
-
Medexus Pharmaceuticals (MDP.V), Flexing its deal making muscles
Buckle up everyone, and get excited – let’s break down Medexus’ latest press release with all its technical details. This is a two-parter, because Medexus not only has closed an important deal that has relevancy for blood cancer treatments, but it’s also upsized its current financing – a financial move that’s indicative of the growing…
-
![Delic Holdings (DELC.C) to acquire industry leading ketamine clinics as plan becomes clearer]()
Delic Holdings (DELC.C) to acquire industry leading ketamine clinics as plan becomes clearer
Regular readers with an interest in psychedelics will know we recently started talking to a company called Delic Holdings (DELC.C), and that it was a company coming to the market, not claiming it had the answers to profitability in a competitive space, or that it would lead the world in this or that but, rather,…
-
![PredictMedix (PMED.C), CFO SECRETLY SOLD SHARES??? (*CLICKBAIT*)]()
PredictMedix (PMED.C), CFO SECRETLY SOLD SHARES??? (*CLICKBAIT*)
Ok weekenders, let’s talk PMED. For the newbies in the room, PMED is PredictMedix Inc, a biotech company Equity Guru’s been working with for the past little bit. (Of course, this doesn’t change the fact that we’re still big on holding people accountable – client or not. See recent example here.) PMED as a business…
-
Does Core One Labs (COOL.C) have a solution for psilocybin’s dosing problem?
Core One’s objective in developing the psilocybin thinstrips is to assist with the delivery of revolutionary psychedelic treatment methods to address mental health conditions such as depression, anxiety and addictions.
-
Core One Labs (COOL.C) acquires 100% of a synthetic psilocybin company
“This transaction will significantly enhance Core One Labs’ ability to innovate our psychedelic drug development program,” stated Joel Shacker, CEO of Core Labs.
-
Immunoprecise Antibodies (IPA.V), or should I say (NASDAQ: IPA)
Before we start, let’s give a big round of applause to Immunoprecise Antibodies Ltd and all its staff and its management. They are headed to the big leagues, ladies and gentlemen – a straight path towards listing on the Nasdaq (begin trading on Nasdaq on December 30th, 2020). I’m not a parent myself (unless you…
-
Perimeter Medical Imaging AI (PINK.V): the power of a simple story
No need to cut the patient open again later. The surgeon can make adjustments on the fly.
-
Can scrappy Valeo Pharma (VPH.C) win a Stanley Cup?
“With more than 8 years of proven in-market safety internationally and a robust supply chain ensuring product availability, we expect Redesca to play a major role in the achievement of our growth objectives,” stated Saviuk.
